Literature DB >> 31334800

Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement.

Douglas K Owens1,2, Karina W Davidson3, Alex H Krist4,5, Michael J Barry6, Michael Cabana7, Aaron B Caughey8, Chyke A Doubeni9, John W Epling10, Alex R Kemper11, Martha Kubik12, C Seth Landefeld13, Carol M Mangione14, Lori Pbert15, Michael Silverstein16, Melissa A Simon17, Chien-Wen Tseng18,19, John B Wong20.   

Abstract

Importance: Screening for hepatitis B virus (HBV) infection during pregnancy identifies women whose infants are at risk of perinatal transmission. Data from a nationally representative sample showed a prevalence of maternal HBV infection of 85.8 cases per 100 000 deliveries from 1998 to 2011 (0.09% of live-born singleton deliveries in the United States). Although there are guidelines for universal infant HBV vaccination, rates of maternal HBV infection have increased annually by 5.5% since 1998. Children infected with HBV during infancy or childhood are more likely to develop chronic infection. Chronic HBV infection increases long-term morbidity and mortality by predisposing infected persons to cirrhosis of the liver and liver cancer. Objective: To update the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for HBV infection in pregnant women. Evidence Review: The USPSTF commissioned a reaffirmation evidence update to identify substantial new evidence sufficient enough to change the prior recommendation. The USPSTF targeted its evidence review on the effectiveness and potential harms of screening and the effectiveness and harms of case management to prevent perinatal transmission. Findings: The USPSTF previously found adequate evidence that serologic testing for hepatitis B surface antigen accurately identifies HBV infection. Interventions are effective for preventing perinatal transmission, based on foundational evidence and observational studies of US case management programs. In addition, there is evidence that over time, perinatal transmission has decreased among women and infants enrolled in case management, providing an overall substantial health benefit. Therefore, the USPSTF reaffirms its previous conclusion that there is convincing evidence that screening for HBV infection in pregnant women provides substantial benefit. Conclusions and Recommendation: The USPSTF recommends screening for HBV infection in pregnant women at their first prenatal visit. (A recommendation).

Entities:  

Mesh:

Year:  2019        PMID: 31334800     DOI: 10.1001/jama.2019.9365

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  Incorrect Language in Figure and Text.

Authors: 
Journal:  JAMA       Date:  2019-09-17       Impact factor: 56.272

2.  Enhancing Electronic Health Systems to End Transmission of Chronic Hepatitis B During COVID-19: A Collaborative Approach.

Authors:  Eric Chak; Fresnia Vu; Julie Dang; Ulissa Smith; Susan Stewart; Karman Tam; Amy Beste-Fong; Breanna Phelps; Ian Johnson; Miguel Suarez; Mary Pat Pauly; Moon S Chen
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-08-05

3.  Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis.

Authors:  Geraldo Duarte; Paula Pezzuto; Tiago Dahrug Barros; Gláucio Mosimann Junior; Flor Ernestina Martinez-Espinosa
Journal:  Rev Soc Bras Med Trop       Date:  2021-05-17       Impact factor: 1.581

4.  Seroprevalence of hepatitis B virus among pregnant women attending Antenatal care in Dilla University Referral Hospital Gedio Zone, Ethiopia; health facility based cross-sectional study.

Authors:  Adugnaw Atnafu Atalay; Reta Kassa Abebe; Aberash Eifa Dadhi; Worku Ketema Bededa
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

Review 5.  Hepatitis B vaccination and immunotherapies: an update.

Authors:  Cristina Stasi; Caterina Silvestri; Fabio Voller
Journal:  Clin Exp Vaccine Res       Date:  2020-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.